Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chelsea’s Hypotension Drug Droxidopa Could Fill Void If FDA Pulls ProAmatine

Executive Summary

The regulatory uncertainty surrounding Shire’s hypotension drug midodrine (ProAmatine and generics) leaves Chelsea Therapeutics International Ltd. in a good position for its newly submitted Northera (droxidopa).
Advertisement

Related Content

FDA Panel Will Weigh Northera’s Short-Term Benefit Vs. Lack Of Durable Effect, Safety Concerns
Chelsea Therapeutics’ Northera Advisory Review May Turn On Validity Of Combined Clinical Trial Analysis
Not The Next Avastin? Plan For New ProAmatine Studies Would Negate Shire’s Withdrawal Hearing Request
BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
Shire’s Request For ProAmatine Hearing Will Go Unanswered Until 2012
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS053882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel